Lixte Biotechnology (LIXT)
Develops LB-100 and proton therapy technology for cancer treatment.
Something off on this page? Send us feedback.
LIXTE Biotechnology is a clinical-stage cancer therapy company centered on LB-100, a PP2A inhibitor studied with chemotherapy and immunotherapy. After acquiring a majority stake in Liora Technologies, it also added an electronically controlled proton therapy platform.
LIXTE Biotechnology Holdings develops oncology treatments around LB-100, a small-molecule inhibitor of protein phosphatase 2A. The company describes LB-100 as a way to make tumor cells more vulnerable to chemotherapy, immune checkpoint therapy, and other cancer treatments, while its current clinical work focuses on ovarian clear cell carcinoma, metastatic microsatellite-stable colorectal cancer, and advanced soft tissue sarcoma.
The ovarian program combines LB-100 with dostarlimab through MD Anderson and Northwestern, and the colorectal study combines LB-100 with atezolizumab through the Netherlands Cancer Institute with Roche support. LIXTE also owns most of Liora Technologies Europe, which is developing the LiGHT electronically controlled proton therapy system. The business remains development-stage, so progress depends on clinical results, regulatory review, partner support, and continued access to capital.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $12.7M · Total debt $1.1M · Total assets $26.6M · Shareholders' equity $23.9M
- Revenue
- $0
- Operating income
- −$2.3M
- Net income
- −$2.2M
No dividends on record.
| Insiders11 holders · as of Jul 2, 2026 | 10.44% | 1.68M shares | |
| Strategic holders1 holder · as of Jun 9, 2026 | 4.81% | 774.9K shares | |
| Otherremainder | 84.75% | 13.65M shares |
16.10M company shares as of Sep 3, 2026 · holders as of their latest filing
Two share counts disagree (16.10M in the company's Sep 3, 2026 report, 12.36M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Strategic EP, LLCStrategic | 4.81% | 774,902 | 13Gfiled Jun 9, 2026 ↗ |
Geordan Garrett PursgloveInsiderdirector, officer: CEO and Chairman of the Board | 4.35% | 700,000 | Form 4filed Jul 2, 2026 ↗ |
Vanguard Capital ManagementInstitution | 3.87% | 622,756 | 13Gfiled Jul 31, 2026 ↗ |
Gil Schwartzberg1Insiderdirector, 10 percent owner | 1.33% | 214,499 | 13G/Afiled Dec 17, 2020 ↗ |
John S. KovachInsiderdirector, 10 percent owner, officer: President and CEO | 0.97% | 156,128 | 13D/Afiled Dec 17, 2020 ↗ |
| See all 24 → | |||
- Gil Schwartzberg's transaction reports restate only vehicles that traded; the 2020 ownership statement (214.5K) is used instead.
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
Not reported.